Nicole Sweeny's most recent trade in KalVista Pharmaceuticals Inc was a trade of 100,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 11, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 100,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 93,750 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 68,750 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 59,291 | 0 (0%) | 0% | 0 | Common Stock | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 40,000 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2026 | 5,000 | 40,000 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2026 | 5,000 | 60,780 (0%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 26.78 per share. | 22 May 2026 | 1,489 | 59,291 (0%) | 0% | 26.8 | 39,872 | Common Stock |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2026 | 6,250 | 57,641 (0%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2026 | 6,250 | 68,750 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 26.78 per share. | 21 May 2026 | 1,861 | 55,780 (0%) | 0% | 26.8 | 49,846 | Common Stock |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 6,250 | 53,253 (0%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 6,250 | 93,750 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 20.22 per share. | 16 Apr 2026 | 1,862 | 51,391 (0%) | 0% | 20.2 | 37,643 | Common Stock |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2026 | 6,250 | 75,000 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2026 | 6,250 | 45,978 (0%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2026 | 5,000 | 50,978 (0%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2026 | 5,000 | 45,000 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 15.57 per share. | 21 Feb 2026 | 3,975 | 47,003 (0%) | 0% | 15.6 | 61,878 | Common Stock |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2026 | 100,000 | 100,000 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 6,250 | 38,541 (0%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 6,250 | 81,250 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 5,000 | 43,541 (0%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 5,000 | 50,000 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 13.45 per share. | 21 Nov 2025 | 3,813 | 39,728 (0%) | 0% | 13.5 | 51,289 | Common Stock |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2025 | 5,000 | 33,771 (0%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Aug 2025 | 5,000 | 55,000 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 13.42 per share. | 22 Aug 2025 | 1,480 | 32,291 (0%) | 0% | 13.4 | 19,862 | Common Stock |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2025 | 6,250 | 30,635 (0%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2025 | 6,250 | 87,500 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 13.22 per share. | 21 Aug 2025 | 1,864 | 28,771 (0%) | 0% | 13.2 | 24,647 | Common Stock |
| Praxis Precision Medicines Inc | Nicole Sweeny | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.94 per share. | 12 Feb 2023 | 1,456 | 38,619 | - | 3.9 | 5,737 | Common Stock |
| Praxis Precision Medicines Inc | Nicole Sweeny | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Praxis Precision Medicines Inc | Nicole Sweeny | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 41,085 | 41,085 | - | - | Stock Option (Right to Buy) | |
| Praxis Precision Medicines Inc | Nicole Sweeny | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.52 per share. | 07 Jan 2023 | 2,079 | 40,075 | - | 2.5 | 5,239 | Common Stock |
| Praxis Precision Medicines Inc | Nicole Sweeny | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Praxis Precision Medicines Inc | Nicole Sweeny | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 8.80 per share. | 13 May 2022 | 2,587 | 42,154 | - | 8.8 | 22,760 | Common Stock |
| Praxis Precision Medicines Inc | Nicole Sweeny | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.85 per share. | 12 Feb 2022 | 1,233 | 39,567 | - | 12.8 | 15,844 | Common Stock |
| Praxis Precision Medicines Inc | Nicole Sweeny | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 84,000 | 84,000 | - | - | Stock Option (Right to Buy) | |
| Praxis Precision Medicines Inc | Nicole Sweeny | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 24,000 | 40,800 | - | 0 | Common Stock |